ArticleScientific reports2026
Assessment of the biochemical basis underlying the resistance against systemic amyloidosis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amyloid resistance is the reduced or abrogated ability of an organism to develop a specific type of amyloid disease. For example, it was found that certain mouse strains show resistance against systemic AA amyloidosis, due to mutations in the amyloid fibril precursor protein serum amyloid A (SAA). In this research, we find that the SAA1.5 and 2.2, two SAA-isoforms that underlie amyloid resistance in mice are unable to adopt the structure of pathogenic AA amyloid fibrils under conditions, where the pathogenic protein variant SAA1.1 does so. Furthermore, molecular dynamics simulations show that the pathogenic fibril structure does not tolerate the sequential changes present in SAA1.5 and 2.2 and becomes distorted by the variant sequences. These data imply that SAA1.5 and SAA2.2 cause amyloid resistance due to a structural incompatibility of their sequences with the specific fold of pathogenic AA amyloid fibrils.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.